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Introduction: Previous studies in animal models of osteoarthritis suggest that alendronate (ALN) has antiresorptive
and chondroprotective effects, and can reduce osteophyte formation. However, these studies used non-physiologic
injury methods, and did not investigate early time points during which bone is rapidly remodeled prior to cartilage
degeneration. The current study utilized a non-invasive model of knee injury in mice to investigate the effect of
ALN treatment on subchondral bone changes, articular cartilage degeneration, and osteophyte formation
following injury.
Methods: Non-invasive knee injury via tibial compression overload or sham injury was performed on a total of 90
mice. Mice were treated with twice weekly subcutaneous injections of low-dose ALN (40 μg/kg/dose), high-dose
ALN (1,000 μg/kg/dose), or vehicle, starting immediately after injury until sacrifice at 7, 14 or 56 days. Trabecular
bone of the femoral epiphysis, subchondral cortical bone, and osteophyte volume were quantified using micro-computed
tomography (μCT). Whole-joint histology was performed at all time points to analyze articular cartilage and
joint degeneration. Blood was collected at sacrifice, and serum was analyzed for biomarkers of bone formation
and resorption.
Results: μCT analysis revealed significant loss of trabecular bone from the femoral epiphysis 7 and 14 days
post-injury, which was effectively prevented by high-dose ALN treatment. High-dose ALN treatment was also able
to reduce subchondral bone thickening 56 days post-injury, and was able to partially preserve articular cartilage
14 days post-injury. However, ALN treatment was not able to reduce osteophyte formation at 56 days post-injury,
nor was it able to prevent articular cartilage and joint degeneration at this time point. Analysis of serum
biomarkers revealed an increase in bone resorption at 7 and 14 days post-injury, with no change in bone
formation at any time points.
Conclusions: High-dose ALN treatment was able to prevent early trabecular bone loss and cartilage degeneration
following non-invasive knee injury, but was not able to mitigate long-term joint degeneration. These data contribute
to understanding the effect of bisphosphonates on the development of osteoarthritis, and may support the use
of anti-resorptive drugs to prevent joint degeneration following injury, although further investigation is warranted.* Correspondence: bchristiansen@ucdavis.edu
Department of Orthopaedic Surgery, University of California-Davis Medical
Center, 4635 2nd Ave, Suite 2000, Sacramento, CA 95817, USA
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Table 1 Summary of animal numbers used in this study
Day 7 Day 14 Day 56
Sham Injured Sham Injured Sham Injured
Vehicle 4 6 4 6 4 6
Low-dose
alendronate
4 6 4 6 4 6
High-dose
alendronate
4 6 4 6 4 6
Khorasani et al. Arthritis Research & Therapy  (2015) 17:30 Page 2 of 11Introduction
Approximately 12% of symptomatic osteoarthritis (OA)
cases are considered post-traumatic OA (PTOA), corre-
sponding to 5.6 million individuals in the United States
being affected by symptomatic PTOA [1]. However,
traumatic joint injuries provide a unique opportunity to
employ treatments aimed at slowing or preventing the
onset of PTOA, as there is an identifiable event that
initiates this process. Treatments aimed at inhibiting
bone turnover are of particular interest, as subchondral
bone is severely affected in OA [2-6], and subchondral
bone changes can often be observed before articular
cartilage degeneration [3,7-9]. Controlling the bone re-
modeling process may also be useful for preventing the
formation of osteophytes, which are a common and
painful outcome of OA development.
The bisphosphonate alendronate (ALN) is a potentially
useful therapeutic option for preventing or slowing the de-
velopment of PTOA. ALN has shown the ability to retain
subchondral and periarticular bone following initiation of
OA in multiple animal models [10-16]. Importantly, ALN
has also exhibited chondroprotective effects [10,12,13,16],
and has exhibited the ability to reduce the formation of
osteophytes [10,12,15]. However, there is some inconsist-
ency in the reported benefits of ALN for preventing OA;
some studies have found no chondroprotective effect in
animals treated with ALN [14], or even a negative effect
on articular cartilage [11].
Previous studies investigating the effect of ALN on OA
development have important limitations. Many studies
have focused on mid- to late-stage OA development, which
may miss crucial early time points in which subchondral
bone undergoes rapid resorption [17]. Another notable
shortcoming in the prior studies is the lack of a non-
invasive method of joint injury to initiate PTOA. Prior
studies typically used invasive surgical means to initiate
PTOA, including anterior cruciate ligament (ACL) tran-
section [10,12,13,16] or medial meniscectomy [12,15].
However, these methods may complicate the outcomes
of the study due to unintended effects from the invasive
surgical procedures. Surgical injury methods may intro-
duce joint swelling or immune response due to the sur-
gical procedures themselves, rather than from the
targeted joint disruption. Disruption of the joint capsule
also likely affects the natural response of the joint to in-
jury; this is particularly concerning at early time points
following injury.
In the current study we investigated the effect of
ALN treatment in mice following non-invasive ACL
rupture induced by tibial compression overload. We
quantified the effect of ALN on early (7 and 14 days
post-injury) and long-term (56 days post-injury) cartil-
age degeneration, subchondral cortical bone thicken-
ing, epiphyseal trabecular bone loss, and osteophyteformation. We hypothesized that ALN treatment would
inhibit the loss of epiphyseal trabecular bone at early
time points, and would decrease long-term subchon-
dral bone thickening, osteophyte formation, and articu-
lar cartilage degeneration. These outcomes would
support the use of ALN for inhibiting PTOA following
traumatic joint injury, as well as provide crucial informa-
tion about the role of bone turnover in the development
of PTOA.
Methods
Animals and experimental groups
A total of 90 C57BL/6N female mice (10 weeks old at
the time of injury) were obtained from Harlan Sprague
Dawley (Indianapolis, IN, USA). Female mice were used
rather than male mice to reduce the added activity due
to fighting, and to eliminate the confounding effect of
individual housing in the event of isolating an aggressor.
Mice were randomized into 18 groups based on treat-
ment duration and dose (Table 1). Mice were sacrificed
at 7, 14 or 56 days post-injury, and were treated twice
weekly with low-dose ALN (ALN-L; 40 μg/kg/dose),
high-dose ALN (ALN-H; 1,000 μg/kg/dose), or vehicle
solution (VEH; phosphate-buffered saline (PBS)). The 7-
and 14-day time points were chosen to quantify the early
trabecular bone loss that we have previously observed
within 1 to 2 weeks of knee injury in mice [17,18], while
the 56-day time point was used as a terminal end point for
fully-developed OA including osteophyte formation and
articular cartilage degeneration [17]. Mice were cared for
in accordance with the guidelines set by the National Insti-
tutes of Health (NIH) on the care and use of laboratory
animals. Mice were housed in Tecniplast conventional
cages (Tecniplast SPA, Buguggiate, Italy), with Bed-o’ Cob
bedding (The Andersons Inc., Maumee, OH, USA), with
four mice per cage, 12-hour light/dark cycle, 20°C to 26°C
ambient temperature. Mice had ad libitum access to food
(Harlan irradiated 2918 chow) and autoclaved water, and
were provided with Enviro-dri and/or Nestlets for envir-
onmental enrichment. Mice were monitored by husbandry
staff at least once a day, 7 days a week, with monthly
healthcare checks by a veterinarian. All procedures were
approved by the institutional Animal Studies Committee
at UC Davis.
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Mice (n = 54; Table 1) were subjected to non-invasive
ACL rupture via tibial compression overload as previously
described [17,18]. Knee injury was induced by a single dy-
namic overload cycle (1 mm/s loading rate) to a target
compressive load of 12 N using an electromagnetic mate-
rials testing system (ELF 3200, Bose, Eden Prairie, MN,
USA). This loading protocol causes ACL rupture with as-
sociated avulsion fracture from the distal femur [17,18].
Knee injury was noted by a release of compressive force
during loading and an audible click. Sham injury was per-
formed by anesthetizing mice (n = 36; Table 1) and apply-
ing a 1-2 N compressive load to the lower leg.
Alendronate treatment
Sixty mice were treated with subcutaneous injection of
alendronate sodium trihydrate (Sigma-Aldrich, St Louis,
MO, USA) twice weekly (1 injection every 3 to 4 days),
starting immediately after injury and lasting until sacri-
fice at 7, 14 or 56 days. ALN-L mice (n = 30) received
doses of 40 μg/kg/dose, while ALN-H mice (n = 30) re-
ceived doses of 1,000 μg/kg/dose. The low-dose and
high-dose treatments were chosen to represent the high
and low range of effective doses from previous studies
[10,19]. VEH mice (n = 30) were injected twice weekly
with a vehicle solution (PBS).
ELISA analysis of serum biomarkers of bone turnover
Serum biomarkers of bone formation and bone resorp-
tion were analyzed at each time point to determine the
effect of joint injury and ALN treatment on bone turnover.
Blood was collected (100 to 200 μL) from each mouse im-
mediately prior to sacrifice; samples were allowed to clot
for 1 to 2 hours, then serum and hematocrit were sepa-
rated using centrifugation at 5,500 RPM at 4°C. Blood
serum was analyzed for cross-linked C-terminal telopep-
tide of type I collagen (CTX-I) and procollagen type
1 N-terminal propeptide (P1NP) (CUSABio ELISA kit,
Wuhan Huamai Biotech Co., Wuhan, China). P1NP is a
common serum biomarker of bone formation, while CTX-I
is a common serum biomarker of bone resorption [20].
Micro-computed tomography imaging
Whole joints were scanned postmortem using micro-
computed tomography (μCT 35, SCANCO, Brüttisellen,
Switzerland) according to the guidelines for μCT analysis
of rodent bone structure [21]: energy 55 kVp, intensity
114 mA, integration time 900 ms, 10 μm nominal voxel
size. Trabecular bone structure was assessed at the dis-
tal femoral epiphysis. The volume of interest for tra-
becular bone included all trabecular bone enclosed by
the growth plate. Trabecular regions were designated
on each two-dimensional transverse slice using manu-
ally drawn contours that excluded the cortical shell andgrowth plate. Trabecular bone volume fraction (BV/
TV), trabecular thickness (Tb.Th), tissue bone mineral
density (BMD; mg HA/cm3), and other trabecular bone
parameters were directly measured using the manufac-
turer’s analysis tools. Subchondral cortical bone was
assessed at the femoral condyles. The cortical volume
of interest included subchondral bone starting at the
distal boundary of the femur, extending up to the distal
boundary of the growth plate, excluding trabecular
bone. Bone volume, cortical thickness (C.Th), and tissue
BMD (mg HA/cm3) were directly measured using man-
ufacturer’s analysis tools. Osteophyte volume, including
all mineralized tissue in and around the joint space,
excluding native mineralized structures such as the pa-
tella, menisci, and fabella, was measured using a separ-
ate contour and was performed on 56-day samples only
(based on our previous studies, mineralized osteophytes
detectable by μCT are not present to a significant de-
gree at 7 or 14 days post-injury). Systemic effects due to
ALN treatment alone (not considering adaptation to in-
jury) were assessed in knees from sham mice.Assessment of articular cartilage via whole-joint histology
Following μCT analysis, whole-joint histology was per-
formed on all samples to quantify articular cartilage and
joint degeneration. Knees were decalcified for 3 days in
15% formic acid and processed for standard paraffin em-
bedding. Sagittal 6 μm sections were cut across the med-
ial aspect of the joint, separated by 250 μm (four
sections for each joint), then stained with Safranin-O
and Fast Green. We performed histological analysis only
on the medial aspect of the joint because this is the pri-
mary site of degeneration for this injury model and
similar animal models [17,18,22-25]. For all sections,
the articular surfaces of the tibia and femur were
graded; blinded slides were graded independently by
three readers using the Osteoarthritis Research Society
International (OARSI) scale [26]. Grades from the three
readers were averaged for each section, then scores for
all gradable sections were averaged for each mouse,
such that each mouse had one grade for tibial cartilage
and one grade for femoral cartilage.Statistical analysis
Statistical analysis included a two-tailed paired t-test to
compare injured limbs to contralateral limbs (the
paired t-test was used for μCT analysis only). Between-
group comparisons for all analyses were performed
within each time point using two-way analysis of vari-
ance (ANOVA) stratified by injury status and treat-
ment, with post hoc analysis using Tukey’s highest
significant difference (HSD) test. Significance was set at
P <0.05 for all tests.
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Trabecular bone analysis via micro-computed
tomography imaging
Knee injury induced significant losses of trabecular bone
in VEH and ALN-L-treated mice by 7 days post-injury,
and persisting until 56 days post-injury, but this effect
was largely blocked in ALN-H mice (Figures 1 and 2).
For example, VEH and ALN-L mice exhibited 27% and
32% lower BV/TV, respectively, in injured versus unin-
jured knees at 7 days post-injury, compared to only 4%
difference in ALN-H mice. At 56 days post-injury, the
injured versus uninjured BV/TV differences were 29%,
16% and 4% for VEH, ALN-L and ALN-H mice, respect-
ively. Trabecular thickness exhibited a similar trend to
BV/TV, with noticeable trabecular thinning in the VEH
and ALN-L groups, with this effect largely prevented inFigure 1 Representative frontal plane cross-sectional images
of the distal femoral epiphysis of injured and sham knees
from each of the treatment groups (from micro-computed
tomography reconstructions). Knee injury initiated trabecular
bone loss in the femoral epiphysis by 7 days post-injury, but this
was largely mitigated by high-dose alendronate (ALN) treatment.
Injured knees also exhibited increased subchondral bone thickness
by 56 days post-injury, but this was also partially blocked by
high-dose ALN treatment. ALN treatment also increased mineralized
tissue volume in the metaphysis, likely due to decreased resorption of
growth plate cartilage.the ALN-H group. At 7 days post-injury, VEH and
ALN-L mice lost 18% and 22% trabecular thickness in
the injured knee, respectively, compared to only 2% differ-
ence in the ALN-H group. By 56 days post-injury, we ob-
served noticeably smaller differences in Tb.Th between
injured and uninjured joints, of 12%, 7% and 3% for the
VEH, ALN-L and ALN-H treatments, respectively.
At 7 and 14 days post-injury, ALN-H mice exhibited sig-
nificantly less trabecular bone loss than VEH or ALN-L
mice for BV/TV and Tb.Th, and VEH and ALN-L mice
generally showed no significant differences from each
other. After 56 days of treatment, however, both ALN-H
and ALN-L mice exhibited attenuated trabecular bone loss
compared to VEH mice, although ALN-H was notably
more effective at preserving trabecular bone volume.
BMD of trabecular bone showed no significant differences
between any groups for any time points.
Treatment of mice with high- and low-dose ALN also
resulted in systemic increases in trabecular bone volume
in sham mice. At 7 and 14 days post-injury ALN-H mice
exhibited 8% to 14% higher BV/TV values than VEH
and ALN-L mice, while ALN-L mice exhibited 2.3% to
2.5% higher values than VEH mice (P <0.05). Fifty-six
days of ALN-H treatment resulted in a significant in-
crease from ALN-L in BV/TV (11.5%) as well as a 22%
increase in BV/TV from VEH to ALN-L. No significant
increases were observed for Tb.Th, and no significant
differences were observed for BMD at any time points.
Quantification of subchondral cortical bone
Subchondral cortical bone of injured knees exhibited re-
duced cortical thickness relative to sham knees at early
time points (14 days post-injury in particular), followed
by significant subchondral bone thickening by 56 days
post-injury (Figures 1 and 2). At 14 days post-injury,
VEH and ALN-L cortical thickness was 8% and 13%
lower in injured knees than sham knees, respectively,
while ALN-H cortical thickness was only 6% lower than
sham. In contrast, at 56 days post-injury, VEH and ALN-L
cortical thickness was 28% and 23% greater in injured
knees than sham knees, respectively, while ALN-H cortical
thickness was only 16% greater than sham. No significant
differences were observed for bone volume or BMD.
Quantification of osteophyte volume
At 56 days post-injury, injured knees exhibited consid-
erable osteophyte formation for all treatment groups
(Figure 3). The pattern of osteophyte formation was
similar to what we have observed in previous studies
[17,18], with osteophytes primarily forming from the
anterior-medial femur and the posterior-medial tibia,
and with considerable hypertrophy of the medial menis-
cus. No statistically significant differences in osteophyte
volume were observed between VEH, ALN-L or ALN-H
Figure 2 Epiphyseal trabecular bone volume fraction (BV/TV; left column), trabecular thickness (Tb.Th; center column), and subchondral
cortical bone thickness (C.Th; right column) at the distal femur at each time point. High-dose alendronate (ALN-H) treatment was able to
preserve trabecular bone volume and trabecular thickness at all time points, and inhibit sclerosis of the subchondral cortical bone at day 56.
ALN-L, low-dose alendronate; VEH, vehicle.
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ume was observed with increased ALN dosage, with
nearly 20% increase in osteophyte volume in ALN-H
knees compared to VEH knees (p = 0.12).
Whole-joint histology analysis of articular cartilage and
joint degeneration
Non-invasive knee injury initiated considerable erosion
of articular cartilage and joint degeneration in the med-
ial compartment of injured knees from all treatment
groups (Figure 4). At 7 days post-injury, only minor cartil-
age degeneration was apparent in injured knees (OARSI
scores of 0 to 3), and no differences were observed
between any experimental groups (data not shown). How-
ever, moderate articular cartilage degeneration was appar-
ent in injured joints by 14 days post-injury, and joint
degeneration was severe in all injured mice by 56 days
post-injury. At 14 days post-injury, the tibial surface of
ALN-H joints exhibited significantly lower OARSI scoresthan VEH joints (1.9 ± 0.9 for ALN-H versus 4.8 ± 0.7 for
VEH). A similar trend was observed on the femoral sur-
face at day 14 as well, although this difference was not sta-
tistically significant. By 7 and 14 days post-injury, injured
joints commonly exhibited considerable fibrous or cartil-
aginous formation at the margins of the joint, particularly
from the anterior femur, posterior tibia, and menisci. By
56 days post-injury, all injured joints had developed severe
OA (OARSI scores of 5+), and no differences were ob-
served between experimental groups. The pattern of
degeneration was similar to what we have observed previ-
ously in 12- and 16-week post-injury knees [18], with sig-
nificant osteophyte formation from the anterior-medial
femur, posterior-medial tibia, and hypertrophy of the
meniscus, particularly the anterior horn. The anterior por-
tion of articular cartilage of the tibia did not appear to be
damaged, most likely due to posterior translation of
the distal femur relative to the tibial plateau because of
joint instability caused by ACL rupture [18]. The posterior
Figure 3 Injured knees all exhibited considerable osteophyte
formation at 56 days post-injury. Left: inferior images of the distal
femur showing the typical pattern of osteophytes. New bone
formation occurred primarily from the anterior-medial femur, the
posterior-medial tibia, and the medial meniscus. Right: alendronate
(ALN) treatment was not effective at preventing osteophyte formation
in injured knees. In fact, there was a trend toward increased osteophyte
formation in high-dose ALN (ALN-H)-treated animals, although this
increase was not statistically significant. ALN-L, low-dose alendronate;
VEH, vehicle.
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ation often extending as far as the growth plate. Lipping
was observed at the posterior tibia, similar to that ob-
served in dogs after cranial cruciate ligament rupture [27],
with new bone formation occurring from the posterior as-
pect of the tibia to increase surface area for the articula-
tion between the femur and tibia. Articular cartilage of the
femur was also worn away, often reaching the subchondral
bone. For the ALN-treated groups, particularly the ALN-
H-treated group, unresorbed cartilage from the growth
plate was present in the metaphysis of both the tibia and
femur, likely due to the absence of osteoclast function.
Serum biomarker analysis
Injured mice exhibited increased levels of serum CTX-I at
all time points compared to uninjured mice for all treat-
ment groups, although this difference was statistically
significant primarily at 14 days post-injury (Figure 5).
ALN-H treatment resulted in lower sCTX-I values than
vehicle at 7 and 14 days (p <0.05). sCTX-I was increased
81% in injured VEH mice at day 7, while at day 14 this dif-
ference was increased to over 300%. In contrast, ALN-L
and ALN-H mice both exhibited approximately 130% in-
creases in sCTX-I at day 14. Serum P1NP (sP1NP) levels
were not found to be significantly different between any of
the experimental groups at any time points (Figure 5).
Discussion
In this study, we used a previously characterized model of
non-invasive ACL injury in mice to determine both theshort-term and long-term effects of ALN on subchondral
bone changes and the development of post-traumatic OA.
Within 7 to 14 days of injury, we observed a significant
loss of trabecular bone in injured knees, consistent with
our previous studies. Low-dose ALN treatment was not
able to prevent this loss of trabecular bone, whereas high-
dose treatment was able to effectively prevent this bone
loss. High-dose ALN treatment was also able to inhibit
articular cartilage degeneration at 14 days post-injury,
although by 56 days post-injury all injured joints exhibited
severe OA regardless of treatment. We also observed
increased serum levels of CTX-I in injured mice at 7 to
14 days, indicative of a rise in bone resorption, while
serum levels of P1NP did not change, indicating no
change in bone formation rate. Contrary to previous stud-
ies [10,12,13,15,16], osteophyte formation was not affected
by ALN use. Altogether, these results confirm the effects
of ALN on bone loss, but only partially support the use of
antiresorptive agents to protect cartilage and decrease
osteophyte formation in OA.
In this study we observed severe joint degeneration in
injured knees of all groups of mice at 56 days post-
injury, and in fact saw notable degeneration by 14 days
post-injury in some mice. This is in contrast to our pre-
vious study using this model, in which we observed only
minor OA at 56 days post-injury [17]. However, our
more recent studies using this model observed a much
more severe OA at 12 and 16 weeks post-injury [18]
and as early as 56 days post-injury [28]. It is unclear
why this more severe degeneration was observed in
these recent studies, as the injury methods are identical.
This may be partially due to the fact that the current
study used female mice rather than male mice as in our
previous study [17], although both male and female
mice were used by Satkunananthan et al. [28], with no
observed sex-based differences in OA severity at 56 days.
Regardless of the underlying reasons, the results of the
current study are consistent with our more recent re-
sults [18,28], and with a surgical mouse model of ACL
transection [23].
Thickening of subchondral cortical bone is a hallmark
symptom of OA. However, a decrease in the structure
of underlying (epiphyseal) trabecular bone during OA
development is also consistent with clinical observations
[3,29,30] and observations from other animal models
[22,25]. Consistent with these observations, injured joints
in this study exhibited a loss of epiphyseal trabecular bone
within 7 days of injury, and a thickening of the subchon-
dral cortical bone by 56 days post-injury, consistent with
OA development in humans. Osteophyte growth is an-
other hallmark symptom of OA. In this study we quanti-
fied mineralized osteophytes with μCT, defined as all
mineralized structures in and around the knee joint, ex-
cluding native mineralized structures (patella, fabella,
Figure 4 Representative sagittal plane histological images of the medial aspect of injured and uninjured knees from vehicle (VEH) and
high-dose alendronate (ALN-H) groups at 14 and 56 days post-injury. ALN-H treatment was able to partially preserve articular cartilage at
14 days post-injury, but was not able to affect joint degeneration at day 56. By 7 to 14 days after injury, fibrous formations are evident on the
anterior-medial femur and posterior-medial tibia in injured joints, with additional fibrous tissue formation from the menisci. By 56 days post-injury,
these fibrous formations have mineralized into osteophytes, and articular cartilage is completely worn away from the posterior surface of the tibia
and the articulating surface of the femur. ALN-L, low-dose alendronate; OARSI, Osteoarthritis Research Society International.
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fication method only measured mineralized tissue volume,
and osteophyte volume obtained using this method is
likely to yield different results than those obtained by hist-
ology (which would include both mineralized and unmi-
neralized new tissue). Additionally, our analysis did not
differentiate between true osteophytes (which are contigu-
ous with the epiphysis of the tibia and femur) and other
heterotopic bone formation around the joint (for example,
new bone formation contiguous with the meniscus). In
this way the osteophyte volume measured by μCT may
not be easily translatable to human OA, because mice
have a greater propensity to ossify soft tissue structures
that are not typically mineralized in humans.
Although high-dose ALN was able to preserve trabecu-
lar bone structure, osteophyte formation was not lessenedby ALN treatment, and articular cartilage was improved
only at an early time point (14 days post-injury). In con-
trast, Hayami et al. observed a chondroprotective and a
significant decrease in osteophyte volume with increasing
dosage of ALN in rats following ACL transection [10].
Jones et al. similarly observed a chondroprotective effect
of ALN and reduced osteophyte formation in rats fol-
lowing a surgical knee triad injury [12]. Similar results
have been observed following monosodium iodoacetate
(MIA) injection in rats [14], medial meniscectomy in
rats [15], ACL transection in rabbits [13,16], and in a
guinea pig model of OA [11]. The cause of the discrep-
ancies between our results and those from other studies
is unclear, but it is possibly due to different animal
models or injury methods. Unlike our mouse-based
study, these previous studies used larger animal models
Figure 5 Serum biomarkers of bone resorption, C-terminal telopeptide of type I collagen (CTX-I) and of bone formation, procollagen
type 1 N-terminal propeptide (P1NP) indicated that structural bone changes observed following injury are due to increased bone
resorption with no change in bone formation. CTX-I exhibited the greatest increase in concentration at 14 days post-injury. This increase was
effectively reduced by alendronate treatment, but remained higher in injured animals than uninjured animals. No significant differences in P1NP
were observed for any experimental groups at any time points. VEH, vehicle; ALN-H, high-dose alendronate; ALN-L, low-dose alendronate.
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critical differences from mice, including considerably
larger body size and thicker articular cartilage. Injury
method could also affect the results of these studies.
ACL transection or other destabilization methods were
used in the majority of these studies, and would therefore
produce altered joint biomechanics similar to our mouse
model. It is currently unclear how these differences in
experimental methods could explain the differences ob-
served in osteophyte and cartilage degeneration. Another
possible complicating factor is the fact that our mouse
model produced severe OA by 56 days post-injury. It is
possible that joint degeneration at this late time point is
unavoidable, and is too severe to show significant benefits
from therapeutic treatments. However, the significant
preservation of articular cartilage with high-dose ALN
treatment at 14 days post-injury is supportive of thebeneficial effects of antiresorptive therapies on PTOA de-
velopment. It is possible that the benefits observed at this
early time point may be more translatable to OA than the
long-term (56 days) observations, as the long-term joint
degeneration in this mouse model is much more severe
than anything observed in human OA. In this way, the
findings from this study may support the use of antire-
sorptive therapies to prevent or slow OA development.
The efficacy of antiresorptive treatments for preventing
OA may depend on several systemic or environmental fac-
tors, such as the rate of systemic bone turnover. For ex-
ample, pamidronate treatment was able to inhibit bone
resorption and reduce OA development after medial men-
iscectomy in ovariectomized mice, in which bone resorp-
tion is dramatically increased [31]. Similarly, pamidronate
decreased OA development following partial medial men-
iscectomy in mice overexpressing runt-related transcription
Khorasani et al. Arthritis Research & Therapy  (2015) 17:30 Page 9 of 11factor 2 (Runx2) under the control of collagen type I, which
display a high bone remodeling phenotype [32]. These find-
ings support the hypothesis that the rate of bone resorption
influences cartilage metabolism and that inhibition might
prevent the progression of OA. The current study used
young wild-type mice, which do not have an accelerated
bone resorption phenotype. This may have affected the
efficacy of ALN treatment in this study, which may be
more beneficial in a background of high bone turnover.
The stage of OA development at which therapy is ap-
plied may be another crucial factor determining the
efficacy of antiresorptive therapies. For example, imme-
diate and early (4 weeks post-medial-meniscus tear)
treatment of rats with zolendronic acid (ZOL) signifi-
cantly improved subchondral bone microstructure, at-
tenuated cartilage degeneration, reduced weight-bearing
asymmetry and calcitonin gene-related peptide (CGRP)
expression, while late (8 weeks post-injury) ZOL adminis-
tration had no significant effects [33]. These data support
the idea of a window of opportunity for antiresorptive
treatments, which may need to be applied during or before
the period of accelerated bone resorption following injury.
In the current study, ALN treatment was applied immedi-
ately after injury, which was able to preserve trabecular
bone mass and partially protect articular cartilage in the
ALN-H group. The time frame for effective ALN treat-
ment following injury remains to be determined.
Our analysis of serum bone metabolism biomarkers
showed an early rise in a biomarker of bone resorption
(sCTX-I) followed by a decline at 56 days post-injury,
while a biomarker of bone formation (sP1NP) remained
unchanged throughout the study period. This indicates
that the early bone changes observed within 14 days of
injury are primarily due to increased bone resorption,
rather than changes in bone formation. The decreases
we observed in sCTX-I with ALN treatment confirm the
ability of ALN to diminish bone resorption. Our obser-
vations corroborate prior studies showing a decrease in
urinary levels of C-terminal telopeptide of type II colla-
gen (CTX-II) and N-terminal telopeptide of type I colla-
gen (NTX-I) with higher dosage of risedronate over
time [34,35]. A clinical study by Nishii et al. using ALN
to treat hip OA in humans also showed a decrease in
urinary NTX-I and CTX-II [36]. It is unclear why we
did not observe a significant increase in P1NP, even at
later time points when there is a strong anabolic re-
sponse and osteophyte formation. It is possible that the
local bone formation response is not strong enough to
affect the systemic levels of P1NP that can be measured
by serum analysis.
Several clinical studies have investigated the effects of
antiresorptive therapies on OA symptoms in human
subjects. A study by Carbone et al. found that ALN use
in OA patients decreased bone abnormalities andattenuated knee pain, yet cartilage degeneration was still
present in the magnetic resonance imaging scans of
treated patients [37]. Spector et al. determined that
risedronate use led to significant improvements in the
Western Ontario and McMaster Osteoarthritis (WOMAC)
index and preservation of knee joint space compared to
placebo in a one-year randomized controlled trial involving
patients with moderate OA [34]. However, a 2-year ran-
domized controlled trial of risedronate treatment revealed
contradictory results, with no significant improvement of
WOMAC score or joint space retention in the knee [38].
Similarly, Nishii et al. observed no inhibition of OA
progression in patients with treated hip OA after 2 years
of ALN treatment [36]. Therefore, in spite of the grow-
ing body of clinical work investigating the subject, no
definitive conclusion can be reached on the practicality
of using bisphosphonates to treat patients with OA. Im-
portantly, all of these studies investigated the use of
bisphosphonates for treating patients who already had
symptomatic OA. We are not aware of any studies that
have used antiresorptive therapies as a preventative
treatment for slowing the progression of OA following a
traumatic joint injury. Our data suggest that ALN may
not be effective for preventing the onset of PTOA fol-
lowing joint injury, but this is in contrast to other stud-
ies that have shown a chondroprotective effect of ALN,
with a decrease in the formation of osteophytes. It is
also important to note that in the current study we ob-
served unresorbed cartilage from the growth plate in
the metaphysis of mice treated with ALN. This observa-
tion is likely not relevant to skeletally mature humans
with closed physes, but could be an important concern
for using antiresorptive treatments in juvenile subjects.
The mouse model used in this study is somewhat lim-
ited because it produces very severe OA by 56 days post-
injury, with much more severe joint degeneration than is
observed in humans. This is a universal limitation for all
mouse models of OA that involve destabilization of the
knee. The tissues of the mouse knee are considerably
smaller than those of humans or larger animals, and de-
generation of the affected joint occurs much faster and to
a much greater extent. However, mouse models of OA are
crucially important for investigating genetic factors that
may increase or decrease the rate of OA development,
and for investigating potential therapies, many of which
have shown beneficial effects. In this context, we feel that
this study is a substantial contribution to the field, because
it uses a non-invasive mechanically induced injury to initi-
ate OA. Additionally, we have included investigation of
early time points (7 and 14 days post-injury) in order to
quantify early or intermediate joint degeneration. The
time points of the current study were chosen in order to
investigate both early subchondral bone loss and late-
stage OA development. However, this excludes many time
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in the development of OA may occur. In spite of this, we
were still able to examine the effect of ALN on changes in
bone that occur both early and late during PTOA. This
study is also somewhat limited because we examined ter-
minal time points at 7, 14, and 56 days post-injury, rather
than comparing longitudinal data from the same mice.
With an imaging modality such as in vivo μCT, longitu-
dinal changes could be directly measured (rather than in-
ferred from cross-sectional data) and the sample size
could be reduced. Nonetheless, using cross-sectional data
at multiple time points, we were still able to confidently
determine the degree to which bone changes occurred in
mice post-injury. Finally, the current study used two dos-
ages of ALN, with the high dose having a 25-fold larger
concentration than the low dose. The absence of an inter-
mediate dose limited our study to the extent that our data
do not inform any conclusions about an optimal dose for
OA therapy, or a threshold at which ALN is effective at
maintaining subchondral bone structure. However, this
limitation did not prevent us from determining with cer-
tainty the effect of high- or low-dose ALN on bone metab-
olism, osteophyte growth, and cartilage damage in our
mouse model of knee injury.
Our study had several key strengths that were able to
address the limitations of previous studies, including the
injury model used and the time points investigated. In
this study we used a non-invasive and reproducible ACL
rupture model in mice that closely mimics ACL injury
in humans. Other studies investigating the effect of
bisphosphonates on PTOA have used invasive or non-
physiologic injury methods such as ACL transection,
medial meniscectomy and MIA injections. By using a
non-invasive injury model, we were able to investigate
bone changes as early as 7 days after injury, which we
have previously shown to be a crucial time for trabecular
bone changes in mice during the development of PTOA
[17]. Previous studies typically began examining struc-
tural changes 2 weeks following initiation of OA [13,14],
which may miss critical early time points during which
there is rapid turnover of subchondral bone.
Conclusion
Using a clinically relevant ACL rupture model, we in-
duced PTOA in mice and analyzed the effect of ALN on
short-term and long-term bone and cartilage degener-
ation. High-dose ALN treatment was able to prevent
early trabecular bone loss and articular cartilage degen-
eration following non-invasive joint injury. However,
ALN was not able to inhibit osteophyte formation, nor
was it able to affect long-term articular cartilage loss or
joint degeneration. Our results also suggest that sub-
chondral bone changes initiated by joint injury are pri-
marily due to increased bone resorption, with littlechange in bone formation at any of the time points
quantified. These data contribute to understanding of
the effect of bisphosphonates on the development of
OA, and may support the use of antiresorptive therapies
for slowing or preventing the onset of PTOA following
injury. However, more research is necessary to confirm
the beneficial effects of antiresorptive therapies for pre-
serving joint health, and to determine the window of op-
portunity for these treatments.
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